It has been reported that market entries of 84 generics, which obtained priority marketing authorization, for 12 pharmaceuticals listed between 2015 and 2023 have saved medication costs of KRW 804.2 billion.

Specifically, it lowered the listed pharmaceutical costs by KRW 536.3 billion and saved through drug substitution by KRW 267.9 billion, totaling KRW 804.2 billion worth of medication cost cuts.

Sales from fourteen generics totaled KRW 397.3 billion, accounting for 49.4% of the total reduction in medication cost. Among these generics was 'Tefovir Tab,' a Viread generic with priority marketing authorization and showed the highest price impact over the past nine years.